Plain-English translation of NCT07290621 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called combined with chemotherapy to treat HPV-positive throat cancer. After receiving the medication and chemotherapy together, you would then receive either robotic surgery or radiation therapy tailored to how well your cancer responded. The goal is to see if adding this immunotherapy helps patients with advanced throat cancer have better outcomes.
Current standard treatment for HPV-positive throat cancer works well for many patients, but doctors want to explore whether adding an immunotherapy medication can improve success rates and potentially allow some patients to avoid more intensive treatments.
You likely qualify if…
You likely don't qualify if…
You would receive infusions combined with chemotherapy over several weeks as the first phase of treatment. After completing this medication phase, you would move on to either robotic surgery to remove the cancer or radiation therapy (sometimes combined with additional chemotherapy), depending on how your cancer responds and other risk factors. The trial involves regular clinic visits for treatment, imaging scans to monitor your progress, and blood tests to check how you're tolerating the therapy.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Chicago
Enrollment target
~30 participants
Started
February 2026
Primary completion
February 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cancer Trials Intake
University of Chicago
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.